what glp-1 drugs are fda approved for weight loss Comparing Ozempic, Wegovy and Other FDA approves new GLP-1 weight

Shortages of the semaglutide-based injectable diabetes medication Ozempic, which accounts for 40% of GLP-1R agonist US market share, have even emerged, driven by overwhelming demand for the weight loss formulation Wegovy , both for treatment of obesity and for short-term weight loss popularized by celebrities on social media

T., Sjoholm, A

By Route of Administration, Injectables Remain the Backbone Through 2035 Injectable formulations account for nearly 99% of obesity GLP-1 therapy use in 2025, reflecting their status as the established delivery route for both semaglutide and tirzepatide

higher dose semaglutide may soon be approved for obesity, while pivotal trial results for orforglipron, mazdutide, retatrutide, and survodutide are anticipated to further expand the therapeutic landscape